for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Glenmark Pharmaceuticals Ltd

GLEN.NS

Latest Trade

471.40INR

Change

2.50(+0.53%)

Volume

2,060,073

Today's Range

470.00

 - 

478.80

52 Week Range

161.65

 - 

573.05

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
468.90
Open
471.00
Volume
2,060,073
3M AVG Volume
60.43
Today's High
478.80
Today's Low
470.00
52 Week High
573.05
52 Week Low
161.65
Shares Out (MIL)
282.17
Market Cap (MIL)
132,308.60
Forward P/E
14.33
Dividend (Yield %)
0.53

Next Event

Q3 2021 Glenmark Pharmaceuticals Ltd Earnings Release

Latest Developments

More

Glenmark Pharma Announces Results Of Umifenovir & Favipiravir Combination Trial For Treating Moderate COVID-19

Glenmark Pharma Introduces Higher Strength (400 Mg) Of FabiFlu

Glenmark Announces Results From Clinical Trial Of Favipiravir For Mild To Moderate COVID-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Industry

Biotechnology & Drugs

Contact Info

B D S Marg

Chakala, Off Western Express Highway

Andheri (E),

400099

India

+91.22.40189999

http://glenmarkpharma.com/

Executive Leadership

Glenn Mario Saldanha

Executive Chairman of the Board, Chief Executive Officer, Managing Director

V. S. Mani

Global Chief Financial Officer, Executive Director

Harish Kuber

Compliance Officer, Company Secretary

Cherylann Pinto

Executive Director - Corporate Services

Blanche E. Saldanha

Non-Executive Director

Key Stats

2.46 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

91.0K

2019

98.7K

2020

106.4K

2021(E)

111.2K
EPS (INR)

2018

28.490

2019

26.860

2020

26.330

2021(E)

32.536
Price To Earnings (TTM)
14.72
Price To Sales (TTM)
1.23
Price To Book (MRQ)
2.04
Price To Cash Flow (TTM)
9.81
Total Debt To Equity (MRQ)
45.55
LT Debt To Equity (MRQ)
39.97
Return on Investment (TTM)
9.54
Return on Equity (TTM)
6.22

Latest News

Latest News

Glenmark's antiviral combination for moderate COVID-19 shows no clinical benefit

India's Glenmark Pharmaceuticals Ltd said on Friday its clinical trial testing a combination of the antiviral drugs umifenovir and favipiravir in moderate hospitalized COVID-19 patients did not show any significant benefit.

Glenmark's favipiravir version shows promise in late-stage COVID-19 trial

India's Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.

Glenmark's favipiravir version shows promise in late-stage COVID-19 trial

India's Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.

India's Glenmark defends price of its COVID-19 drug favipiravir version

Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu, on Tuesday, after India's drug regulator had reportedly sent the company a notice on overpricing.

Glenmark shares fall as India's drug regulator sends notice on overpricing

India's drug regulator has sent a notice to Glenmark Pharmaceuticals Ltd <GLEN.NS> on overpricing and false claims of its generic version of favipiravir, FabiFlu, local media reports said, sending shares down as much as 5.8% on Monday.

Glenmark cuts price of COVID-19 drug favipiravir version to $1 per tablet

Glenmark Pharmaceuticals Ltd said on Monday it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees ($0.9983) per tablet for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India.

U.S. charges generic drug firm Glenmark with price-fixing

Glenmark Pharmaceuticals USA was charged on Tuesday with conspiring to fix prices for generic drugs, the U.S. Justice Department said in a statement.

BRIEF-Hindustan Unilever Ltd Says Completes Acquisition Of Vwash From Glenmark Pharmaceuticals

* HINDUSTAN UNILEVER LTD - HINDUSTAN UNILEVER COMPLETES ACQUISITION OF VWASH FROM GLENMARK PHARMACEUTICALS Source text for Eikon: Further company coverage:

Glenmark gets India approval for favipiravir as COVID-19 treatment

Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country, it said on Friday.

Glenmark gets India approval for favipiravir as COVID-19 treatment

Glenmark Pharmaceuticals Ltd said on Friday it had received an approval from India's drugs regulator to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 patients in the country.

BRIEF-Glenmark Pharmaceuticals Gets Indian Regulator Nod For Favipiravir

* INDIAN REGULATOR APPROVES FAVIPIRAVIR FOR TREATMENT OF MILD TO MODERATE COVID-19 IN INDIA

India's Glenmark to study potential COVID-19 drug combination

Glenmark Pharmaceuticals Ltd <GLEN.NS> said on Tuesday it would begin a clinical trial in India to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential COVID-19 treatment.

India's Glenmark to study potential COVID-19 drug combination

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential COVID-19 treatment.

BRIEF-Glenmark Pharmaceuticals Launches 3-In-1 Inhaler Therapy For COPD In India

* GLENMARK INTRODUCES 3-IN-1 INHALER THERAPY FOR COPD IN INDIA Source text for Eikon: Further company coverage:

Glenmark to conduct trials in India for potential COVID-19 drug

Glenmark Pharmaceuticals Ltd <GLEN.NS> said on Thursday it will start clinical trials in India of antiviral drug favipiravir, seen as a potential treatment for COVID-19, sending its shares up as much as 9%.

India's Glenmark to conduct trials for potential COVID-19 drug, shares jump

Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

BRIEF-Glenmark Gets Regulator Nod For Clinical Trials In India On Favipiravir Antiviral Tablets For COVID-19 Patients

* RECEIVES APPROVAL FROM REGULATOR (DCGI) TO CONDUCT CLINICAL TRIALS IN INDIA ON FAVIPIRAVIR ANTIVIRAL TABLETS FOR COVID-19 PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma Gets ANDA Tentative Approval For Dapagliflozin & Saxagliptin Tablets

* GETS ANDA TENTATIVE APPROVAL FOR DAPAGLIFLOZIN & SAXAGLIPTIN TABLETS, 10 MG/5 MG Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharmaceuticals-Gets ANDA Tentative Approval For Dapagliflozin Tablets 5, 10 MG

* GLENMARK PHARMACEUTICALS LTD -RECEIVES ANDA TENTATIVE APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG Source text for Eikon: Further company coverage:

BRIEF-India's Glenmark Pharma & UK's Hikma Enter Exclusive Licensing Agreement For Nasal Spray In U.S.

* SAYS CO, HIKMA ENTER EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZING RYALTRIS™ SEASONAL ALLERGIC RHINITIS NASAL SPRAY IN US

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up